Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
Can procalcitonin be used as a marker for endothelial dysfunction emanating from chronic inflammation of obesity?
Related Questions
What do you recommend to your patients to prevent muscle loss when prescribing a GLP-1 agonist for weight loss?
How long do you typically treat patients with phentermine for weight loss and what clinical markers do you follow?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
Would you consider changing a non-diabetic patient with obesity and a history of CAD who is on semaglutide to tirzepatide if they have not achieved their weight loss goals?
How many days prior to elective major surgery do you recommend holding oral GLP 1 R agonist therapy?
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
Why is it recommended to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after tirzepatide initiation but not with semaglutide?
In patients with severe obesity, do you recommend a trial of GLP 1 R agonist therapy prior to bariatric surgery?
When treating fatty liver disease with resmetirom, how often should a FibroScan be repeated to assess treatment response?
